Nektar Therapeutics NKTR

$39.84 -1.33 (-3.23%)

Valuation

Market cap
1,405,667,000
Revenue TTM
$55,230,000
Net income TTM
$-164,080,000
PE ratio
0.00
Forward PE
—
Profit margin
-297.08%
Debt to equity
0.00

Trading

Volume
954,229
Avg volume
1,172,254
Day's range
$39.26 – $40.93
Shares out
34,143,000
Stochastic %K
11%
Beta
1.26
Analysts
Strong Sell
Price target
$132.73

Price

Company profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat...

Show more

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Industry
Biotechnology
Sector
Healthcare
Phone
415 482 5300
Website
https://www.nektar.com
Address
455 Mission Bay Boulevard South, San Francisco, United States

Latest news

Stocktwits

Quantumup Oct 12, 3:32 PM
UBS🏁 $NKTR and said: We initiate coverage of Nektar Therapeutics (NKTR) with a Neutral rating and a $53 PT. $REGN - SNY LLY GALD $ABBV PFE INCY QTTB Leerink🏁Nektar: Outperform-$130/said—Rezpeg, a pot'ly first-in-class biologic that stimulates regulatory T-cells through the IL-2 receptor, has a multi-blockbuster opportunity—novel mechanism w/ pot'l application across many immunology indications—models combined gross peak sales of $4B—sees current share levels as a favorable entry point. Here's what UBS went on to say in its initiation report: https://x.com/Quantumup1/status/2109668440893964358?s=20
0 replies
Tipcadog Oct 12, 12:00 PM
$NKTR More than half of adults with atopic dermatitis report inadequately controlled disease despite treatment with currently available biologics that target type 2 inflammation, underscoring the complexity of treating this heterogeneous disease and leaving a major unmet need for a novel approach to immune modulation," said Emma Guttman-Yassky, M.D., Ph.D., Waldman Professor of Dermatology and Immunology and Health System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai. "These data show that rezpegaldesleukin's novel approach to regulatory Tcell stimulation has the potential to treat patients with heterogeneous disease in atopic dermatitis and other autoimmune disease settings." Dr. Guttman-Yassky continued, "Within 2 weeks of treatment, we observed significant systemic and cutaneous normalization across multiple disease associated pathways
0 replies
Tipcadog Oct 12, 11:57 AM
$NKTR continued…Importantly, these early molecular changes correlated with clinical outcomes at Week 16 only in the rezpegaldesleukin-treated patients, providing a meaningful link between the biological activity of rezpegaldesleukin and the subsequent clinical benefit."
0 replies
BK217 Oct 11, 6:49 PM
$NKTR it’s not good when these are your fellow shareholders
0 replies
calbucs Oct 11, 1:23 AM
$NKTR The Paid per post short hoes are in full force here . Trash ! Daddy Short have their BOTS out in full force . Paid by LLY … trying to destroy their competition , sadly did not pay enough for their crooked ways .. block away !
0 replies
BK217 Oct 9, 4:22 PM
$NKTR that guy is getting absolutely railed
1 replies
george4it Oct 9, 3:55 PM
$NKTR Block out the noise and stay the course. I’m still adding at these ridiculously low prices.
0 replies
BK217 Oct 9, 2:09 PM
$NKTR fucccccc this seeeed
0 replies